Thought occurred to me which is like a lightening strike and probably won't happen twice in one day. So I read we got some hires from Merck. Merck is also the Big Pharma that was supposed to get Onolcommune(sp?) drug to help severe critical, but they threw that to the wayside. From the article I read the FDA brought those two together to try and help get that drug to market faster, but it was just too complicated to make. Along comes the next big thing Leronlimab, now on FDA radar but a small company. We know NP is not selling a single indication like Merck got from the other company. Could the FDA be saying "Can you give this company some much needed help in proper filing and setting up drug trials to succeed?"...I know Mahboob ain't around anymore and Brothen isn't listed on the website anymore...is it because big pharma had talent to borrow CYDY, perhaps even better than what we had and they became expendable?
I'm just thinking out loud, and this is absolute total speculation, but I know the FDA did a prearranged "marriage" between Merck and Onolcommune so perhaps they are "guiding" something here because we have a promising drug, but the talent to get everything the way the FDA wants it was a bit lacking.
Note, I don't know who the new hires are that have been mentioned or their positions. So this may be a bit far fetched.